Ligand Pharmaceuticals Incorporated
LGND
$193.03
-$2.07-1.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 251.23M | 187.58M | 181.49M | 167.13M | 152.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 251.23M | 187.58M | 181.49M | 167.13M | 152.42M |
| Cost of Revenue | 96.49M | 79.79M | 78.58M | 32.50M | 32.37M |
| Gross Profit | 154.74M | 107.79M | 102.91M | 134.63M | 120.06M |
| SG&A Expenses | 93.03M | 89.06M | 86.50M | 78.65M | 69.04M |
| Depreciation & Amortization | 32.87M | 33.03M | 33.03M | 32.96M | 33.04M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 222.39M | 201.88M | 198.11M | 144.11M | 134.45M |
| Operating Income | 28.85M | -14.30M | -16.63M | 23.02M | 17.98M |
| Income Before Tax | 62.98M | -84.50M | -161.11M | 2.52M | 58.82M |
| Income Tax Expenses | 14.40M | -8.63M | -28.49M | 6.55M | 13.57M |
| Earnings from Continuing Operations | 48.58 | -75.86 | -132.62 | -4.03 | 45.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.58M | -75.86M | -132.62M | -4.03M | 45.24M |
| EBIT | 28.85M | -14.30M | -16.63M | 23.02M | 17.98M |
| EBITDA | 63.03M | 19.73M | 18.16M | 58.26M | 53.50M |
| EPS Basic | 2.39 | -3.99 | -7.12 | -0.05 | 2.63 |
| Normalized Basic EPS | 1.42 | -0.61 | -0.71 | 0.62 | 0.21 |
| EPS Diluted | 2.07 | -4.00 | -7.12 | -0.16 | 2.51 |
| Normalized Diluted EPS | 1.31 | -0.62 | -0.71 | 0.62 | 0.21 |
| Average Basic Shares Outstanding | 77.07M | 75.91M | 74.61M | 73.15M | 71.65M |
| Average Diluted Shares Outstanding | 78.72M | 76.51M | 74.61M | 73.54M | 72.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |